The Cerulean team is committed to developing products to improve treatment options for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a growing portfolio of nanoparticle-drug conjugate (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations.
Our lead platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials. Our lead indication is ovarian cancer. Our second platform-generated NDC clinical candidate, CRLX301, is in Phase 2a clinical development for the treatment of advanced solid tumors.